Merck's Keytruda snags I-O's first cervical cancer nod to back up HPV fighter Gardasil

Merck’s Keytruda has a new indication, and with it, immunotherapy has moved into a new frontier.

With a Monday FDA green light for certain previously treated cervical cancer patients whose disease has worsened on or after chemotherapy, Keytruda became the first drug in its class to win a nod to treat those with the disease.